Company research / ABEO

Abeona Therapeutics Inc. (ABEO)

SEC name ABEONA THERAPEUTICS INC. · CIK 0000318306 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Partial revenue. In this company's filings, net income for the year ended 2025-12-31 is larger than reported revenue. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.

Key ratios (year ended 2025-12-31)

44.7%
Return on year-end equity

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-29

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$25.52M$5.82Mn/a$3.50M$1.41M$3.00M$10.00Mn/a$3.00M$837.0K$889.0K
Cost of Revenuen/a$1.53Mn/an/an/an/an/an/an/an/an/a
Gross Profit (computed)n/a$4.29Mn/an/an/an/an/an/an/an/an/a
R&D Expense$25.50M$26.81M$34.36M$31.09M$28.96M$38.73M$30.14M$48.57M$38.70M$16.99M$10.65M
Operating Income-$83.61M-$89.45M-$64.21M-$47.13M-$50.91M-$89.84M-$81.42M-$77.09M-$58.17M-$27.84M-$23.88M
Depreciation & Amortization$2.83M$2.55M$2.00M$2.29M$3.09M$3.25M$4.59M$7.82M$2.36M$741.0K$825.0K
EBITDA-$80.79M-$86.90M-$62.21M-$44.85M-$47.82M-$86.59M-$76.83M-$69.27M-$55.81M-$27.09M-$23.06M
Net Income-$62.89M$71.18M-$63.73M-$54.19M-$39.70M-$84.94M-$84.23M-$76.28M-$56.67M-$27.32M-$21.87M
EPS (Diluted)n/a$1.01-$1.55-$2.53-$5.53n/an/an/an/an/an/a
Total Assets$179.51M$219.57M$108.93M$64.00M$64.21M$79.59M$151.20M$223.38M$174.40M$178.77M$111.06M
Total Liabilities$51.45M$60.35M$64.90M$49.18M$37.45M$37.22M$48.65M$44.95M$40.35M$8.67M$11.96M
Long-Term Debt$14.99M$20.04M$18.96Mn/an/an/an/an/an/an/an/a
Shareholders' Equity$128.06M$159.22M$44.03M$14.83M$26.76M$42.37M$102.55M$178.43M$134.04M$170.10M$99.10M
Cash & Equivalents$56.23M$78.44M$23.36M$14.47M$14.22M$32.94M$12.60M$129.26M$18.75M$137.75M$69.14M
Operating Cash Flow-$76.44M-$76.33M-$56.02M-$37.01M-$43.48M-$65.67M-$35.02M-$62.82M-$39.11M-$22.66M-$13.01M
Capital Expenditures$5.09M$7.97M$2.45M$331.0K$130.0K$4.15M$1.34M$6.31M$9.24M$860.0K$519.0K
Free Cash Flow-$81.53M-$84.30M-$58.46M-$37.34M-$43.61M-$69.82M-$36.35M-$69.13M-$48.35M-$23.52M-$13.53M
Shares Outstanding57.23M55.04M45.64M26.52M17.72M5.89M96.13M83.62M47.94M46.89M40.25M
Weighted Average Diluted Sharesn/a66.14M41.05M21.38M7.86Mn/an/an/an/an/an/a
EPS (Basic)n/a$1.34-$1.55-$2.53-$5.53-$21.57n/an/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView